



RECEIVED  
CENTRAL FAX CENTER  
FEB 15 2006

**Attorneys at Law**  
919 N. Market Street  
P.O. Box 111  
Wilmington, DE 19801-3023  
Phone 302.984.6300  
Fax 302.984.6399  
[www.mccarter.com](http://www.mccarter.com)



Total Number of Pages: 13 (Including this Cover Page)

TO: USPTO	FAX NO: 571-273-8300
FROM: Basil S. Krikelis	REGISTRATION NO.: 41,129
TELEPHONE NO.: (302) 984-6393	FAX NO.: (302) 984-6399
FIRST INVENTOR: Orn Adalsteinsson	EXAMINER: Chen, Stacy Brown
TITLE OF APPL: GLUCOSAMINE AND EGG FOR REDUCING INFLAMMATION	
SERIAL NO: 10/774,021	FILING DATE: FEBRUARY 6, 2004
ART UNIT: 1648	CONFIRMATION NO. 7718
LIST OF ATTACHMENTS: Transmittal Form – 1 Page; Amendment in Response to Notice for Non-compliant Amendment – 11 Pages	
Comments:	
The information contained in the facsimile message is attorneys' privileged and confidential information intended only for the person or entity named above. If you are not the intended recipient (or someone responsible to deliver to the intended recipient), please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us by telephone immediately at (302) 984-6300 and return the original message to us at the above address via the U. S. Postal Service. Thank you.	

WL1:100727.01

TEST AVAILABLE COPY

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10774,021	
	Filing Date	February 6, 2004	
	First Named Inventor	Om Adalsteinsson	
	Art Unit	1848	
	Examiner Name	Chan, Stacy Brown	
Total Number of Pages in This Submission	12	Attorney Docket Number	ARK-153US1

**RECEIVED**  
**CENTRAL FAX CENTER**  
**FEB 15 2006**


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	McCarte & English, LLP		
Signature			
Printed name	Basil S. Krikells		
Date	February 15, 2006	Reg. No.	41,129

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Reece L. Sipple	Date	February 15, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Appln. No.: 10/774,021  
Non-Compliant Amendment Dated January 24, 2006  
Reply to Non-Compliance of January 18, 2006

ARK-153US1

Appln. No: 10/774,021  
Applicant: Orn Adalsteinsson  
Filed: February 6, 2004  
Title: GLUCOSAMINE AND EGG FOR REDUCING INFLAMMATION  
TC/A.U.: 1648  
Examiner: Chen, Stacy Brown  
Confirmation No.: 7718  
Docket No.: ARK-153US1

**RECEIVED**  
**CENTRAL FAX CENTER**  
**FEB 15 2006**

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: February 15, 2006

  
Renee L. Sipple

**AMENDMENT IN RESPONSE TO**  
**NOTICE FOR NON-COMPLIANT AMENDMENT (37 CFR 1.121)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Non-Compliance mailed January 18, 2006 please amend the above-identified application as follows:

- ☒ **Amendments to the Specification** begin on page 2 of this paper.
- ☒ **Amendments to the Claims** are reflected in the listing of claims which begins on page 4 of this paper.
- ☒ **Remarks/Arguments** begin on page 8 of this paper.